Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Starton Holdings, Inc.

CIK 2049977Updated Oct 29, 2026

No exchange listing on record for this SEC filer. Coverage is drawn from its filings.

Filing activity

SEC EDGAR
Latest filing

S-1/A · Oct 28, 2026

6 filings on record · S-1/A.

About the company

We are a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems. We use continuous delivery of FDA-approved, active ingredients in an attempt to develop and bring products to market in either new indications or with enhanced outcomes in existing indications. In collaboration with our consulting company, McKinsey & Company, we evaluated over 80,000 potential applications to identify those applications where we believed our continuous delivery technology would bring the most benefit to patients. Based on the results of that evaluation, we are focused initially on the treatment of hematologic malignancies (blood cancers). Our algorithms also seek to identify drug candidates in areas of significant unmet medical needs that have not been able to achieve FDA approval due to tolerability concerns. This process allows us to prioritize targeted opportunities.

S-1/A · 2026-10-28 · 0001213900-26-113388

Company description from the cited filing.

Recent filings

  1. S-1/A filing

    S-1/A · 2026-10-28 · 0001213900-26-113388

  2. S-1/A filing

    S-1/A · 2026-07-13 · 0001213900-26-077653

  3. S-1/A filing

    S-1/A · 2026-06-09 · 0001213900-26-066466

  4. S-1/A filing

    S-1/A · 2026-04-07 · 0001213900-26-040616

  5. S-1/A filing

    S-1/A · 2026-03-13 · 0001213900-26-027771

Show 1 more recent filings
  1. S-1/A filing

    S-1/A · 2026-01-30 · 0001213900-26-009696

Offerings

Registration 333-292059

S-1/A · 2026-10-28 · 0001213900-26-113388

Terms from the governing filing for this registration; not a claim that the offering is open today.

Underwriters: Sentinel Brokers Company, Inc., Revere Securities LLC

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.